Recombinant multi-species SLC25A6 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SLC25A6 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene is a member of the mitochondrial carrier subfamily of solute carrier protein genes. The product of this gene functions as a gated pore that translocates ADP from the cytoplasm into the mitochondrial matrix and ATP from the mitochondrial matrix into the cytoplasm. The protein is implicated in the function of the permability transition pore complex (PTPC), which regulates the release of mitochondrial products that induce apoptosis. The human genome contains several non-transcribed pseudogenes of this gene. [provided by RefSeq, Jun 2013]
The Alternative Names of target: AAC3,ADP,ADP/ATP translocase 3,ANT,ANT 2,ANT 3,ANT3,ANT3Y,ATP carrier protein,ATP carrier protein 3,Adenine nucleotide translocator 3 (ANT 3),SLC25A6,Solute carrier family 25 member 6,isoform T2 (ANT 2)
Go
to SLC25A6 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP1692-Ag-1/ GM-Tg-hg-IP1692-Ag-2 | Human SLC25A6 protein | Human |
| GM-Tg-rg-IP1692-Ag-1/ GM-Tg-rg-IP1692-Ag-2 | Rat SLC25A6 protein | Rat |
| GM-Tg-mg-IP1692-Ag-1/ GM-Tg-mg-IP1692-Ag-2 | Mouse SLC25A6 protein | Mouse |
| GM-Tg-cynog-IP1692-Ag-1/ GM-Tg-cynog-IP1692-Ag-2 | Cynomolgus/Rhesus macaque SLC25A6 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP1692-Ag-1/ GM-Tg-felg-IP1692-Ag-2 | Feline SLC25A6 protein | Feline |
| GM-Tg-cang-IP1692-Ag-1/ GM-Tg-cang-IP1692-Ag-2 | Canine SLC25A6 protein | Canine |
| GM-Tg-bovg-IP1692-Ag-1/ GM-Tg-bovg-IP1692-Ag-2 | Bovine SLC25A6 protein | Bovine |
| GM-Tg-equg-IP1692-Ag-1/ GM-Tg-equg-IP1692-Ag-2 | Equine SLC25A6 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-IP1692-Ag-1/ GM-Tg-hg-IP1692-Ag-2;
GM-Tg-rg-IP1692-Ag-1/ GM-Tg-rg-IP1692-Ag-2;
GM-Tg-mg-IP1692-Ag-1/ GM-Tg-mg-IP1692-Ag-2; GM-Tg-cynog-IP1692-Ag-1/ GM-Tg-cynog-IP1692-Ag-2; GM-Tg-felg-IP1692-Ag-1/ GM-Tg-felg-IP1692-Ag-2; GM-Tg-cang-IP1692-Ag-1/ GM-Tg-cang-IP1692-Ag-2; GM-Tg-bovg-IP1692-Ag-1/ GM-Tg-bovg-IP1692-Ag-2; GM-Tg-equg-IP1692-Ag-1/ GM-Tg-equg-IP1692-Ag-2 |
| Products Name | SLC25A6 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | SLC25A6 |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SLC25A6 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.